Real-time evaluation of macozinone activity against Mycobacterium tuberculosis through bacterial nanomotion analysis
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.01318-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Anthony Vocat und 11 weiteren Autor:innen. Beteiligte Einrichtung: Resistell AG, Muttenz, Switzerland. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Antitubercular Agents, Thiazines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Novel drugs and improved diagnostics for Mycobacterium tuberculosis (MTB) are urgently needed and go hand in hand. We evaluated the in vitro activity of two benzothiazinone drug candidates (MCZ, PBTZ169; BTZ043) and their main metabolites against MTB using advanced nanomotion technology. The results demonstrated significant reductions in MTB viability within 7 h, indicating the potential for rapid, precise antibiotic susceptibility testing based on a phenotypic read-out in real time. PBTZ169 and H 2 -PBTZ169 achieved 100% separation between the susceptible H37Rv and a resistant dprE1 mutant strain NTB1. These findings support nanomotion technology’s potential for faster antibiotic susceptibility testing of novel MTB drug candidates targeting the DprE1 enzyme that could reduce empirical treatment duration and antibiotic resistance selection pressure due to inaccurate treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Resistell AG, Muttenz, Switzerland.
- Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- Innovative Medicines for Tuberculosis (iM4TB), Lausanne, Switzerland.
- Service of Infectious Diseases, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- Research Centre of Biotechnology RAS, Leninsky Prospect, Moscow, Russia.
ORCID-Profile: Gilbert Greub, Vadim Makarov, Stewart T Cole, Alexander Sturm
Zitieren
APA
Vocat, A., Luraschi-Eggemann, A., Antoni, C., Cathomen, G., Cichocka, D., Greub, G., Riabova, O., Makarov, V., Opota, O., Mendoza, A., Cole, S. T., & Sturm, A. (2025). Real-time evaluation of macozinone activity against Mycobacterium tuberculosis through bacterial nanomotion analysis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01318-24
Vancouver
Vocat A, Luraschi-Eggemann A, Antoni C, Cathomen G, Cichocka D, Greub G, et al. Real-time evaluation of macozinone activity against Mycobacterium tuberculosis through bacterial nanomotion analysis. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01318-24
BibTeX
@article{Vocat2025,
author = {Vocat, Anthony and Luraschi-Eggemann, Amanda and Antoni, Claudia and Cathomen, Gino and Cichocka, Danuta and Greub, Gilbert and Riabova, Olga and Makarov, Vadim and Opota, Onya and Mendoza, Alfonso and Cole, Stewart T and Sturm, Alexander},
title = {Real-time evaluation of macozinone activity against Mycobacterium tuberculosis through bacterial nanomotion analysis},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.01318-24}
}
EUVIMED